Episode
Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye
- Podcast
- Cell & Gene: The Podcast
- Published
- Mar 12, 2026
- Duration seconds
- 1684
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/scaling-crispr-for-rare-disease-with-aurora-therapeutics-dr-edward-kaye/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/cell-gene-the-podcast-4048431/scaling-crispr-for-rare-disease-with-aurora-therapeutics-dr-edward-kaye.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye ...